Impact of Sweeteners on Behaviour, Physiology & Health

Inclusion Criteria: * BMI: 25 to 35 kg/m2 * Use of contraceptive methods or not planning to become pregnant for the duration of the study (women only) * Regular consumption of sugar-containing foods and willing to consume sugar and artificially-sweetened food products. * Liking of the intervention foods defined by a response of Yes for the product during the pre-screening interview and a score of 40% or above on the Liking Visual Analogue Scale for the sucrose-sweetened control product. * Able to participate on the Clinical Investigation Days during normal working hours. * Healthy as determined from the self-reported medical history or when a clinical condition exists, when this is considered to be irrelevant (i.e. not influencing study outcomes) for the study by the study medical doctor. * Consuming breakfast regularly (at least 5 days per week). * Able to understand and be willing to sign the informed consent form, and to follow all the study procedures and requirements. * Capacity to store at-home intervention quantity of intervention product Exclusion Criteria: * Blood donation \< 3 month prior to study or for full duration of the study. * Food allergy, intolerance, restriction or avoidance of any of the study foods (e.g. veganism) or history of anaphylactic reaction to any food. * Likelihood for disordered eating defined as a score ≥20 on the Eating Attitudes Test. * Currently dieting to lose weight. * Having lost or gained \>4.5 kg in the last 3 months. * Smoking or having quit \<3 months prior to study. * Habitually consuming \>14 units/week of alcohol in women or \>21 units/week in men in the last 3 months. * Performing \>10 h of intense physical activity per week in the last 3 months. * Night or late shift work (ending later than 11 pm on a permanent basis). Rotational shift work allowed if can attend on days that do not follow a late/night shift. * Self-reported use of drugs of abuse within the previous 12 months. * Pregnancy, lactation (women only) * Persons who do not have access to either (mobile) phone or internet (this is necessary when being contacted by the study personnel during the study). * Insufficient communication in the national language. * Proven or suspected inability, physically or mentally, to comply with the procedures required by the study protocol as evaluated by the daily study manager, site-PI, PI or clinical responsible. This includes volunteers for which insufficient collaboration may be foreseen. * Subject's general condition contraindicates continuing in the study as evaluated by the daily study manager, site-PI, PI or responsible clinician. * Simultaneous participation in other relevant clinical intervention studies. * Previous university or college training related to eating behaviour research. * Self-reported eating disorders. * Diagnosed anaemia. * Diagnosed diabetes mellitus. * Abnormal G.I. function or structure such as malformation, angiodysplasia, active peptic ulcer. * Active inflammatory bowel disease, celiac disease, chronic pancreatitis or other disorder potentially causing malabsorption. * History of G.I. surgery with permanent effect (i.e. surgical treatment of obesity). * Medical history of Cardiovascular Disease (e.g. current angina; myocardial infarction or stroke within the past 6 months; heart failure; symptomatic peripheral vascular disease). * Significant liver disease, e.g. cirrhosis (fatty liver disease allowed). * Malignancy which is currently active or in remission for less than five years after last treatment (local basal and squamous cell skin cancer allowed). * Thyroid diseases, except those on Levothyroxine treatment of hypothyroidism if the person has been on a stable dose for at least 3 months. * Psychiatric illness (e.g. major depression, bipolar disorders). * Use currently or within the previous 3 months of prescription or over the counter medication that has the potential of affecting appetite, satiety or body weight incl. food supplements. Except: low dose antidepressants if they, in the judgement of the daily study manager, site-PI, PI or clinical responsible, do not affect weight or following the study protocol. Levothyroxine for treatment of hypothyroidism is allowed if the person has been on a stable dose for at least 3 months. * Cholesterol lowering medication, if the dose has changed during the last 3 months (i.e. the medication is allowed if the participant has been on a stable dose for at least 3 months).